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Abstract
Rationale: Idiopathic multicentric Castleman disease (iMCD) is a systemic disease with multiple regions of lymphadenopathy and
systemic symptoms and associated with rheumatoid arthritis (RA) and collagen diseases. However, few reported have described the
coexistence of iMCD and RA and the mechanisms by which iMCD induces arthritis remain elusive. We experienced a rare case of
iMCD, wherein the patient exhibited symptoms of polyarthritis with high-grade fever.
Patient concerns: A 34-year-old woman was admitted to our hospital for further evaluation of a high fever with polyarthritis. The
levels of both rheumatoid factor and anticitrullinated protein antibody were negative. 18F-fluorodeoxyglucose/positron emission
tomography-computed tomography showed lymphadenopathy with increased fluoro-2-deoxy-D-glucose uptake. Magnetic
resonance imaging and musculoskeletal ultrasonography revealed active synovitis in the hands which was consistent with RA.
Diagnoses: We diagnosed iMCD based on human herpesvirus 8 negativity, HIV negativity, systemic lymphadenopathy, and
pathologic findings of the lymph nodes. The patient did not satisfy the 2010 American College of Rheumatology and European
League Against Rheumatism classification criteria for RA. Cytokine assay showed elevated serum levels of interleukin-17 and
CXCL10, comparable to those in patients with RA.
Interventions: We administered 15mg/d of predonisolone.
Outcomes: After this treatment, the patient’s symptoms showed improvement. As of this writing, we tapered the prednisolone to
7.5mg/d, and the patient’s remission has been maintained for >4 months.
Lessons:The present case suggests that RA-like active synovitis may coexist in iMCD, resulting from aberrant T-cell activation and
histologic examination using lymph node biopsy may help enable early diagnosis of iMCD.
Abbreviations: CD=Castleman disease, CRP=C-reactive protein, EBV= Epstein–Barr virus, FDG= fluoro-2-deoxy-D-glucose,
18F-FDG/PET-CT = 18F-fluorodeoxyglucose/positron emission tomography-computed tomography, IL = interleukin, iMCD =
idiopathic multicentric Castleman disease, MCD =multicentric Castleman disease, MSUS =musculoskeletal ultrasonography, PSL
= prednisolone, RA = rheumatoid arthritis, UCD = unicentric Castleman disease, VEGF = vascular endothelial growth factor.
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Castleman disease (CD) is a rare lymphoproliferative disease; its
pathology was 1st reported by Benjamin Castleman in 1956.[1]
CD is classified into unicentric CD (UCD) and multicentric CD
(MCD), based on the number of regions of enlarged lymph nodes
with characteristic histopathologic features.[2] Patients with UCD
typically have focal lymph nodes and are generally asymptomatic
or mildly symptomatic; in contrast, MCD is a systemic disease
with multiple regions of lymphadenopathy and systemic
symptoms that include fever, night sweats, weight loss, and
fatigue.
The etiology of MCD remains largely unclear. The observed
clinical symptoms of MCD are attributed to hypercytokinemia,
including elevated levels of interleukin-6 (IL-6).[3] MCD can be
divided into the human herpesvirus 8 infection-related MCD
and idiopathic MCD (iMCD).[4] Majority of the patients with
UCD are treatable via surgical excision. The prognosis of
iMCD varies, and the achievement of remission can be
challenging.
The iMCD is associated with rheumatoid arthritis (RA) and
collagen diseases[5]; therefore, some patients with iMCD develop
arthritis. However, the mechanisms by which iMCD induces
arthritis remain elusive.
We experienced the case of a patient with iMCD who
developed arthralgia. This patient had active synovitis
detected by magnetic resonance imaging (MRI) and muscu-
loskeletal ultrasonography (MSUS). In this case, cytokine
analysis revealed increased levels of IL-17 and CXCL10,
suggesting the involvement of T-cell activation in the
mechanism responsible for the development of synovitis in
iMCD.Table 1
Laboratory investigations in the present case.
Blood count
WBC 6700 /mL PLT
RBC 3.44 106/mL ESR
Hb 8.7 g/dL
Blood chemistry
CRP 10.14 mg/dL Alb
Na 136 mmol/L T-Bil
K 3.8 mmol/L AST
Cl 102 mmol/L ALT
BUN 12 mg/dL ALP
Cr 0.55 mg/dL LDH
UA 3.7 mg/dL CK
TP 8.3 g/dL GLU
Immunologic test
RF <3.6 IU/mL Anti-Sm Ab
ACPA <0.6 IU/mL Anti-SS-A Ab
MMP-3 2705.7 ng/mL Anti-ARS Ab
ANA 1: 1280 (SP) Anti-RNP Ab
Infection
Chlamydia DNA –
T-SPOT.TB – CMV C7-HRP –
Parvovirus B19 IgM – HHV-8 DNA –
EBV Past infection HIV –
ACPA= anticitrullinated peptide antibodies, Alb= albumin, ALP=alkaline phosphatase, ALT= alanine tra
chlorine, CMV= cytomegalovirus, Cr= creatinine, CRP=C-reactive protein, EBV=Epstein–Barr virus, Hb
LDH= lactate dehydrogenase, MMP-3=matrix metalloproteinase-3, MPO-ANCA=myeloperoxidase antine
cytoplasmic antibody, RBC= red blood cells, RF= rheumatoid factor, sIL-2R= soluble interleukin-2 rec
endothelial growth factor, WBC=white blood cells.
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2. Case report
The healthy 34-year-old woman had experienced arthralgia at
the shoulders, wrists, and ankles for a period of 2 months.
Subsequently, she presented with a high fever and swelling of
fingers and visited a local orthopedic clinic. Thereafter, she was
admitted to our hospital for further evaluation of fever of
unknown origin with polyarthritis in May 2018.
On admission, her body temperature was 37.5°C, blood
pressure 86/54 mm Hg, and heart rate 80 bpm. A physical
examination showed swollen lymph nodes in the left neck and
both axillae. Laboratory investigations (Table 1) showed reduced
hemoglobin (Hb) (8.7g/dL) and albumin levels (2.9g/dL), with
elevated serum C-reactive protein (CRP) (10.14mg/dL), IL-6
(111.69pg/dL), and vascular endothelial growth factor (VEGF)
(202.57pg/dL) levels. Immunologic studies showed antinuclear
antibody 1280-fold (speckled type); however, all specific
autoantibodies were negative. Cytomegalovirus antigenemia
assay and Epstein–Barr virus (EBV) DNA were also negative.
An examination with 18F-fluorodeoxyglucose/positron emission
tomography-computed tomography (18F-FDG/PET-CT) showed
multiple lymphadenopathy with increased fluoro-2-deoxy-D-
glucose (FDG) uptake (Fig. 1A). In addition, FDG accumulation
was observed in her joints (Fig. 1A). Although no erosion was
detected by the X-ray in the hands and feet, MRI revealed active
synovitis and tenosynovitis in the right hand (Fig. 1B). MSUS
assessment of the hands, elbows, and ankles showed synovial
thickening with remarkable PD signals (Fig. 1C). Left axillary
lymph node biopsy revealed blood vessels at the atrophied
germinal center along with the accumulation of CD3+ T cells,
CD20+ B cells, and CD138+ plasma cells consistent with CD
(Fig. 2).55.6 104/mL
114 mm/h
2.9 g/dL Hb-A1c 5.5 %
0.5 mg/dL TSH 0.737 mIU/mL
20 U/L FreeT4 1.37 ng/dL
17 U/L IgG 2086 mg/dL
286 U/L IgG4 25.9 mg/dL
162 U/L Ferritin 288 ng/mL
25 U/L sIL-2R 757 U/mL
85 mg/dL
1.2 IU/L MPO-ANCA <1.0 U/mL
1.6 IU/mL PR3-ANCA <1.0 U/mL
<5.0 IL-6 111.69 pg/mL
2 IU/mL VEGF 202.57 pg/mL
nsaminase, AST= aspartate transaminase, BUN=blood urea nitrogen, CK= creatinine kinase, Cl=
=hemoglobin, HHV-8=human herpesvirus 8, HIV=human immunodeficiency virus, K=potassium,
utrophil cytoplasmic antibody, Na= sodium, PLT=Platelets, PR3-ANCA=proteinase-3 antineutrophil
eptor, SP= speckled type, T-bil= total bilirubin, TP= total protein, UA=uric acid, VEGF= vascular
Figure 1. (A) Fluoro-2-deoxy-D-glucose accumulation visible in her left cervical lymph node (red arrows); axillary lymph nodes (red arrows); as well as elbow wrist,
knee, and ankle joints (blue arrows). (B) Magnetic resonance imaging shows active synovitis and tenosynovitis in her right hand (yellow arrows). (C) Musculoskeletal
ultrasonography assessment in the 1st metacarpophalangeal joint and carpal joints show synovial thickening with high-intensity power Doppler signals (yellow
arrows). Synovial thickening is present in the humeroradial joint (yellow arrows).
Figure 2. Left axillary lymph node biopsy reveals blood vessels at the atrophied germinal center with the accumulation of lymphocytes (hematoxylin and eosin [HE]
staining, original magnification 200). Immunohistochemical stains show CD3+ T cells, CD20+ B cells, and CD138+ plasma cells (DAB and HE staining, original
magnification 200).
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Figure 3. The clinical course of the present patient. The graphs display the arthritis severity, C-reactive protein (CRP) level, CHAP score, and treatment interventions.
Otsuka et al. Medicine (2019) 98:18 MedicineWe made a diagnosis of iMCD on the basis of international,
evidence-based consensus diagnostic criteria.[6] We excluded infec-
tion,malignancy, and autoimmune disorders that canmimic iMCD.
Thedisease severity in this patientwas classified asmild based on the
criteria proposed in Japan.[7] The patient’s findings did not fulfill the
2010 American College of Rheumatology and European League
AgainstRheumatismclassificationcriteriaforRA.[8]Accordingly,we
initiated 15mg/day of prednisolone (PSL) in mid-June 2018, and it
reduced the arthritis, fatigue, fever, and lymphadenopathy aswell asFigure 4. Comparisonof the serumcytokine levels of patientswith rheumatoid arthrit
standard error of mean (SEM); RA with HDA: n=83; HCs: n=133. IL= interleukin;
4
normalizedthe levelsofHb,albumin,andCRP.Atthetimeofwriting
this report, we tapered the PSL to 7.5mg/day, and the patient’s
remissionhas beenmaintained for>4months. The clinical course of
the patient has been shown in Figure 3. We evaluated her disease
activity based on the recently proposed CHAP score.[7] We
investigated her serum cytokine levels at diagnosis before PSL
initiation.HerIL-6,IL-17,andCXCL10levelswerehigherthanthose
ofhealthycontrols;however, the tumornecrosis factoralpha,VEGF,
and fractalkine levels did not show such a trend (Fig. 4).is (RA)with highdiseaseactivity (HDA) and thoseof healthy controls (HCs).Mean±
TNFa= tumor necrosis factor alpha; VEGF=vascular endothelial growth factor.
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Weexperienced a rare case of iMCD,wherein the patient exhibited
symptoms of polyarthritis with high-grade fever and was treated
successfully with a low dose of PSL. She presented with RA-like
active synovitis in her hands. To our knowledge, none of the
reviews on rheumatic diseases complicatedwith CD have reported
the case of a patient with iMCD complicated with RA.[9] Further,
to the best of our knowledge, no investigations have been
performed to evaluate arthritis in iMCD patients using FDG/PET-
CT, MRI, and MSUS. Synovitis detected using MRI or MSUS is
useful for the early diagnosis of RA.[10] It is noteworthy that based
on some reports, PD signal positive synovitis predicts future RA
development in patients with undifferentiated arthritis.[11,12]
MSUS and MRI findings of the synovitis in her fingers and wrist
joints were consistent with RA. Therefore, although her synovitis
disappeared rapidly following treatment with PSL alone without
subsequent relapse, she may develop RA in the future.
We compared the serum cytokine levels of this patient and
patients with RA. The serum IL-6 level was higher in our patient
than those in patients with RA with high disease activity;
moreover, the concentrations of IL-17 and CXCL10 were
comparable to those of patients with RA. CXCL10 (also known
as interferon-g-inducible 10-kD protein [IP-10]) is a chemokine
that may play a role in the immunopathogenesis of RA.[13]
CXCR3, preferentially expressed on Th1 cells, is the receptor of
CXCL10, suggesting that CXCL10 induces the migration of Th1
cells.[13,14] Therefore, we believed that the Th1 cells as well as the
activation of Th17 cells contributed to active synovitis in the
present case.
The IL-6 is an inflammatory cytokine that is implicated in the
pathogenesis of both, iMCD and RA[15]; however, active arthritis
is rare in patients with iMCD. In fact, IL-6 transgenic mice do not
exhibit symptoms of active synovitis with bone erosion.[16] In this
case, we observed elevated cytokines related to T-cell activation,
indicating that T cells may have contributed to the development
synovitis in combination with IL-6. Consistent with the finding of
a large number of CD3+ T cells in the lymph node in our patient,
T cells are reportedly activated in the lymph nodes in patients
with iMCD.[17] Thus, the role of T cells in the development of
arthritis should be investigated in the future.
To conclude, we experienced the case of a patient with iMCD
that developed with RA-like active synovitis and was detected
using MRI and MSUS. Active arthritis is rarely observed in
iMCD; therefore, the activation of T cells with increased IL-6
levels was considered to contribute to the development of arthritis
in this case. The present case suggests that RA-like active
synovitis may coexist in iMCD and histologic examination using
lymph node biopsy may help enable early diagnosis of iMCD.
Further case studies and functional studies are warranted to
clarify the mechanisms underlying the development of active
arthritis in patients with iMCD.Acknowledgment
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